TITLE

ATHEROSCLEROSIS: CRITICAL ROLE OF OXIDATION AND INFLAMMATION

AUTHOR(S)
SUBHAPRIYA, S.; TOMI, LINTO; PADMANABAN, V. C.
PUB. DATE
October 2013
SOURCE
International Journal of Pharmacy & Pharmaceutical Sciences;2013 Supplement 4, Vol. 5 Issue Supp 4, p6
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Atherosclerosis - cardiovascular disorder which involves progressive narrowing and degeneration of arteries. The oxidative modification of low density lipoproteins (LDL) in the arterial wall by reactive oxygen species (ROS), elevated levels of homocysteine in blood plasma are the key risk factors for atherosclerosis. Importantly, several processes are triggered by other risk factors, including the expression of adhesion molecules, the proliferation ad migration of smooth muscle cells, the apoptosis of endothelial cells, the oxidation of lipids, the activation of metalloproteinase and the alteration of vasomotor activity. Eventually in its natural progression, calcification of the atheromatous plaque occurs. Depending on the affected artery in the body, the related disorders include coronary heart disease, carotid artery disease peripheral arterial disease and chronic kidney disease.
ACCESSION #
93366165

 

Related Articles

  • STABILITY: Darapladib misses primary endpoint in stable CHD population. Ellis, Brian; Kalvaitis, Katie; Swain, Erik; Taliercio, Adam // Cardiology Today;Apr2014, Vol. 17 Issue 4, p16 

    The article reports that the use of darapladib, a drug for atherosclerosis being investigated by pharmaceutical firm GlaxoSmithKline, failed to significantly lower the risk for cardiovascular death, myocardial infarction or stroke in patients with stable coronary heart disease (CHD).

  • Combination nanotherapy penetrates atherosclerosis. Mulder, Willem J. M. // Cardiovascular Research;Feb2016, Vol. 109 Issue 2, p191 

    No abstract available.

  • Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study. Ureña-Torres, Pablo A.; Floege, Jürgen; Hawley, Carmel M.; Pedagogos, Eugenie; Goodman, William G.; Pétavy, Frank; Reiner, Maureen; Raggi, Paolo // Nephrology Dialysis Transplantation;Jan2013, Vol. 28 Issue 1, p146 

    Background The ADVANCE study assessed the progression of vascular and cardiac valve calcification in 360 hemodialysis patients with secondary hyperparathyroidism (sHPT) assigned randomly to treatment either with cinacalcet plus low-dose vitamin D (≤6 µg/week of intravenous paricalcitol...

  • Predicting plaque rupture: enhancing diagnosis and clinical decision-making in coronary artery desease. Fischer, A.; Gutstein, D.E.; Fayad, Z.A.; Fuster, V. // Vascular Medicine;2000, Vol. 5 Issue 3, p163 

    Atherosclerosis is the process underlying coronary artery disease, myocardial infarction and cerebrovascular disease and is a leading cause of morbidity and mortality in industrialized countries. The atherosclerotic plaque is often indolent and progressive and may destabilize without warning....

  • CARDIOVASCULAR AND CORONARY RISK ESTIMATION IN HYPERTENSION MANAGEMENT. Wallis, Erica J.; Ramsay, Lawrence E.; Jackson, Peter R. // Heart;Sep2002, Vol. 88 Issue 3, p306 

    Explores the principle and practice of using absolute cardiovascular disease or coronary heart disease risk for decisions on antihypertensive treatment. Importance of absolute risk in hypertension; Possible harm from treating low risk patients; Accuracy of Framingham risk estimates; Additional...

  • Extent of Coronary Atherosclerosis and Homocysteine Affect Endothelial Markers. Yildinir, Aylin; Tokgozoglu, S. Lale; Haznedaroglu, Ibrahim; Sinici, Incilay; Kabakci, Giray; Ovunc, Kenan; Aksoyek, Serdar; Oto, Ali; Ozmen, Ferhan; Kirazli, Serafettin; Kes, Sirri // Angiology;Sep2001, Vol. 52 Issue 9 

    Evaluates the effects of the presence, extent and clinical stability of coronary artery disease on endothelial function parameters, C-reactive protein and homocysteine levels. Diagnosis of coronary atherosclerosis; Presence of vascular cell adhesion molecule-1 and sE-selectin; Leukocyte counts.

  • UCLA pharmacists take patient education to heart. Gebhart, Fred // Drug Topics;5/21/2001, Vol. 145 Issue 10, p29 

    Offers information on the Cardiovascular Hospitalization Atherosclerosis Management Program conducted by pharmacists at the University of California Los Angeles Medical Center. Findings from the study; Regimen recommended by the program to coronary heart disease patients; Measures that have made...

  • Cholesterol-lowering drug can inhibit or reverse CAD lesions.  // Geriatrics;May94, Vol. 49 Issue 5, p57 

    Features an abstract of the article `Coronary angiographic changes with lovostatin therapy: The Monitored Atherosclerosis Regression Study,' by D.H. Blankenhorn, S.P. Azen et al which was originally published in the 1993 issue of the `Annual Internal Nedicine' periodical. Study protocol; Findings.

  • EDTA Didn't Relieve Symptoms Of Ischemic Heart Disease.  // RN;Mar2003, Vol. 66 Issue 3, p26 

    Reports that ethylenediaminetetraacetic acid did not relieve symptoms of ischemic heart disease. Leaching out of calcium from atherosclerotic plaque.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics